theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

COVID-19

Rituximab   

Questions discussed in this category


Is there a role for antibody testing to confirm vaccine response for patients on rituximab after COVID-19 vaccination?
1 Answer available

How will you use REGEN-COV (casirivimab/imdevimab-monoclonal antibody treatment recently approved under EUA as post-exposure prophylaxis for Covid) in rheumatic patients on immunosuppressive therapy?
Would you consider this for patients on B-cell depleting therapies or more broadly for other immunosuppressive agents?
2 Answers available

Are there particular concerns related to the use of B-cell depletion therapies such as rituximab for rheumatic disease during the COVID-19 pandemic?
1 Answer available
10024106068621


Papers discussed in this category


Rheumatol Int, 2020 Sep 18
High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study.

N Engl J Med, 2021 Aug 04
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.

Related Topics in COVID-19

  • Breast Cancer
  • Head and Neck Cancers
  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Gastrointestinal Cancers
  • Genitourinary Cancers
  • Melanoma/Skin Cancer
  • Non-malignant Disease
  • Pediatric Hematology/Oncology

Copyright © 2025 theMednet
All Rights Reserved.